Boehringer Ingelheim, a Germany-based biopharmaceutical company, announced on Friday that it has received a Commissioner's National Priority Voucher (CNPV) for HERNEXEOS (zongertinib tablets).
HERNEXEOS is currently under investigation for first-line use in treatment-naive patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC).
The CNPV program looks to reduce the review process from a typical tome-scale of 10-12 months to one to two months, while maintaining the FDA's rigorous safety and efficacy standards.
This honour is claimed to reflect the potential of HERNEXEOS to meet critical patient requirements for this rare and aggressive cancer.
The FDA chose HERNEXEOS for the CNPV program.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval